Moderna (MRNA) just joined the NASDAQ-100 Index. This move can reshape how large institutional investors treat the stock and influence how you think about its role in a portfolio.
Recent price action has been intense. Moderna’s 7 day share price return of 15.4% and 30 day gain of 50.2% feed into a roughly 7x 1 year total shareholder return, while a 5 year total shareholder return that is down 35.2% shows how volatile the ride has been.
A 216.7% 90 day share price return, together with index inclusion, positive late stage oncology data and a new Chief Operating Officer, suggests momentum has recently shifted as investors reassess both growth optionality and risk around the mRNA pipeline.
Seize this momentum shift around Moderna and scan a curated set of late stage healthcare mRNA and biotech opportunities with the 33 healthcare AI stocks.Moderna now looks like a rebuilt story stock, with an mRNA platform, oncology data and index status in its corner. At US$216.25 a share, is that strength fairly priced, or already overpaid?
Most Popular Narrative: 76% Overvalued
Against a narrative fair value of $122.67, Moderna’s last close at $216.25 reflects a wide gap that puts expectations in the spotlight.
The dramatic expansion and advancement of Moderna's mRNA pipeline beyond COVID 19 including recent positive late stage data and upcoming filings for flu, RSV, CMV, oncology, and rare diseases are likely to diversify the revenue base, capitalize on the rising global burden of infectious and chronic diseases, and materially boost future top line growth.
See why 219 investors see Moderna as 76% overvalued.
Result: Fair Value of $122.67 (OVERVALUED)
Still, the narrative can break if COVID era vaccine demand keeps fading faster than new products ramp up, or if regulatory delays slow Moderna’s broader mRNA rollout.
Find out about the key risks to this Moderna narrative.
Next Steps
Sentiment around Moderna is clearly split, with strong optimism and clear concerns running side by side. Use the full data set to pressure test your own thesis and move quickly while you weigh 1 key reward and 1 important warning sign.
Looking for more Moderna investment ideas?
If Moderna has sharpened your focus on opportunity and risk, you can use that same energy to hunt for other stocks that could round out your portfolio and reduce single name reliance.
- Target resilience by scanning a 32 resilient stocks with low risk scores that can help you balance Moderna's volatility with steadier performers.
- Hunt for mispriced quality using a 32 high quality undervalued stocks that highlights companies where fundamentals and price tell two very different stories.
- Stack income potential alongside growth by reviewing a 8 dividend fortresses that focuses on businesses offering higher yields with staying power.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com